Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 227

1.

Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.

Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL.

J Urol. 2008 Oct;180(4):1432-7; discussion 1437. doi: 10.1016/j.juro.2008.06.017. Epub 2008 Aug 16.

PMID:
18710748
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.

Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R.

J Urol. 2008 Oct;180(4):1438-43; discussion 1443-4. doi: 10.1016/j.juro.2008.06.029. Epub 2008 Aug 16.

PMID:
18710743
[PubMed - indexed for MEDLINE]
3.

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.

Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL.

J Urol. 2005 May;173(5):1567-71. Erratum in: J Urol. 2005 Aug;174(2):796. Sartor, Oliver [added]; Higano, Celestia S [added]; Petrylak, Daniel P [added] Chatta, Gerkamal [added].

PMID:
15821487
[PubMed - indexed for MEDLINE]
4.

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL.

J Urol. 2009 Mar;181(3):1104-13; discussion 1113. doi: 10.1016/j.juro.2008.11.026. Epub 2009 Jan 23.

PMID:
19167733
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.

Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20.

PMID:
22438406
[PubMed - indexed for MEDLINE]
Free Article
6.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
[PubMed - indexed for MEDLINE]
7.

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.

Urology. 1999 May;53(5):898-902; discussion 902-3.

PMID:
10223480
[PubMed - indexed for MEDLINE]
8.

The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.

Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K.

J Urol. 2007 Oct;178(4 Pt 1):1282-8; discussion 1288-9. Epub 2007 Aug 14.

PMID:
17698092
[PubMed - indexed for MEDLINE]
9.

A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.

Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC.

J Urol. 2000 Dec;164(6):1891-4.

PMID:
11061874
[PubMed - indexed for MEDLINE]
10.

Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.

Pathak AS, Pacificar JS, Shapiro CE, Williams SG.

J Urol. 2007 Jun;177(6):2132-5; discussion 2135.

PMID:
17509298
[PubMed - indexed for MEDLINE]
11.

A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.

Prapotnich D, Cathelineau X, Rozet F, Barret E, Mombet A, Cathala N, Sanchez-Salas RE, Vallancien G.

World J Urol. 2009 Oct;27(5):627-35. doi: 10.1007/s00345-009-0393-1. Epub 2009 Feb 27.

PMID:
19247669
[PubMed - indexed for MEDLINE]
12.

Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.

Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.

BJU Int. 2008 May;101(9):1096-100. doi: 10.1111/j.1464-410X.2007.07374.x. Epub 2008 Jan 8.

PMID:
18190637
[PubMed - indexed for MEDLINE]
13.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.

BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.

PMID:
19035858
[PubMed - indexed for MEDLINE]
14.

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K.

Urology. 1995 May;45(5):839-44; discussion 844-5.

PMID:
7538246
[PubMed - indexed for MEDLINE]
15.

Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?

Perachino M, Cavalli V, Bravi F.

BJU Int. 2010 Mar;105(5):648-51. doi: 10.1111/j.1464-410X.2009.08814.x. Epub 2009 Aug 28.

PMID:
19747358
[PubMed - indexed for MEDLINE]
16.

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.

Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group.

J Urol. 2008 Sep;180(3):915-9; discussion 919-20. doi: 10.1016/j.juro.2008.05.009. Epub 2008 Jul 17.

PMID:
18635219
[PubMed - indexed for MEDLINE]
17.

Cellular changes in prostate cancer cells induced by intermittent androgen suppression.

Laitinen S, Martikainen PM, Tammela TL, Visakorpi T.

Eur Urol. 2007 Sep;52(3):725-32. Epub 2006 Nov 28.

PMID:
17141945
[PubMed - indexed for MEDLINE]
18.

Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.

Pickles T, Agranovich A, Berthelet E, Duncan GG, Keyes M, Kwan W, McKenzie MR, Morris WJ; British Columbia Cancer Agency, Prostate Cohort Outcomes Initiative.

Cancer. 2002 Jan 15;94(2):362-7.

PMID:
11900222
[PubMed - indexed for MEDLINE]
19.

Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.

D'Amico AV, Renshaw AA, Loffredo B, Chen MH.

Cancer. 2007 Oct 15;110(8):1723-8.

PMID:
17828774
[PubMed - indexed for MEDLINE]
Free Article
20.

Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.

Takizawa I, Hara N, Nishiyama T, Isahaya E, Hoshii T, Takahashi K.

J Urol. 2010 Nov;184(5):1971-6. doi: 10.1016/j.juro.2010.06.115.

PMID:
20884032
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk